schulungsressourcen

schulungsressourcen

Erkunden Sie die Bildungsprogramme der IMPACT Academy – unterstützt von unserem fachkundigen Lenkungsausschuss

Featured
NEUIGKEITEN

Empfohlener Inhalt

COVID-19 and its implications in heart failure
PRÄSENTATION
COVID-19 and its implications in heart failure
Inhalt anzeigen
Can new-onset diabetes be prevented by dapagliflozin? Insights from DAPA-HF
PRÄSENTATION
Can new-onset diabetes be prevented by dapagliflozin? Insights from DAPA-HF
Inhalt anzeigen
Practicalities of SGLT2 inhibition – pros vs cons
INFOGRAPHIC
Practicalities of SGLT2 inhibition – pros vs cons
Inhalt anzeigen
Updates on ESC heart failure guidelines
VIDEO
Updates on ESC heart failure guidelines
Inhalt anzeigen
Dapagliflozin: Cardiologist Practical Guide to Prescribing Dapagliflozin
INFOGRAPHIC
Dapagliflozin: Cardiologist Practical Guide to Prescribing Dapagliflozin
Inhalt anzeigen
Cardiovascular
NEUIGKEITEN

Herz-Kreislauf

Mechanisms behind the cardiovascular benefits of SGLT2 inhibitors
VIDEO
Mechanisms behind the cardiovascular benefits of SGLT2 inhibitors
Inhalt anzeigen
What did DAPA-HF tell us about the safety of dapagliflozin in heart failure?
INFOGRAPHIC
What did DAPA-HF tell us about the safety of dapagliflozin in heart failure?
Inhalt anzeigen
Hiding in plain sight – how to detect heart failure in primary care
VIDEO
Hiding in plain sight – how to detect heart failure in primary care
Inhalt anzeigen
Optimizing HF discharge care and follow-up
INFOGRAPHIC
Optimizing HF discharge care and follow-up
Inhalt anzeigen
Metabolic
NEUIGKEITEN

Metabolisch

Managing Type 2 Diabetes Beyond Glycemia : Cardiorenal risk in T2D
VIDEO
Managing Type 2 Diabetes Beyond Glycemia : Cardiorenal risk in T2D
Inhalt anzeigen
The benefits of SGLT2 inhibitors in type-2 diabetes, chronic kidney disease and heart failure
INFOGRAPHIC
The benefits of SGLT2 inhibitors in type-2 diabetes, chronic kidney disease and heart failure
Inhalt anzeigen
Clinical recommendations for the management of type 2 diabetes
VIDEO
Clinical recommendations for the management of type 2 diabetes
Inhalt anzeigen
Managing type 2 diabetes beyond glycemia: cardiorenal risk in T2D
INFOGRAPHIC
Managing type 2 diabetes beyond glycemia: cardiorenal risk in T2D
Inhalt anzeigen
Renal
NEUIGKEITEN

Nieren

Chronic kidney disease management
VIDEO
Chronic kidney disease management
Inhalt anzeigen
Renal protection with SGLT2 inhibitors: what every cardiologist should know
INFOGRAPHIC
Renal protection with SGLT2 inhibitors: what every cardiologist should know
Inhalt anzeigen
Kidney outcomes associated with inhibition of SGLT2
VIDEO
Kidney outcomes associated with inhibition of SGLT2
Inhalt anzeigen
SGLT2 inhibitors and dapagliflozin in chronic kidney disease
INFOGRAPHIC
SGLT2 inhibitors and dapagliflozin in chronic kidney disease
Inhalt anzeigen
Blickpunkt
NEUIGKEITEN

Aktuelle Inhalte

The story of heart failure prevention with SGLT2 inhibitors in diabetes: Key learnings for cardiologist
PRÄSENTATION
The story of heart failure prevention with SGLT2 inhibitors in diabetes: Key learnings for cardiologist
Inhalt anzeigen
Dapagliflozin: Cardiologist Practical Guide to Prescribing Dapagliflozin
INFOGRAPHIC
Dapagliflozin: Cardiologist Practical Guide to Prescribing Dapagliflozin
Inhalt anzeigen
Safety and tolerability of SGLT2 inhibitors – how and when should I initiate treatment
VIDEO
Safety and tolerability of SGLT2 inhibitors – how and when should I initiate treatment
Inhalt anzeigen
Cardiorenal benefits of SGLT2 inhibitors
PRÄSENTATION
Cardiorenal benefits of SGLT2 inhibitors
Inhalt anzeigen
Diagnosis and co-morbidities of chronic kidney disease
VIDEO
Diagnosis and co-morbidities of chronic kidney disease
Inhalt anzeigen